European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Purpose of Investigation: Recurrence rates in patients with early cervical cancer are generally low. So far, no biomarker has been found to be associated with the risk of recurrence. In other carcinomas, expression of cell cycle regulators and proliferation markers like ki67 corresponded with tumour stage. The expression of those markers were examined in relapsed early cervical cancer after radical vaginal trachelectomy (RVT) to verify if they are suitable for risk stratification. Materials and Methods: We examined the expression rates of p16, p21, pRb, and cyclin D1 and ki67. Between March 1995 and March 2013, 310 patients with early cervical cancer underwent RVT as fertility-sparing surgery for early cervical cancer. Until now, ten patients suffered from recurrence. The results of relapsing and non-relapsing tumours were compared. Results: p21 was expressed heterogeneously. Neither of the relapsed adenocarcinomas showed an expression of pRb, whereas two of the recurrent squamous cell carcinomas showed positivity of pRb. Adenocarcinomas who relapsed showed a significant lower level of nuclear cyclin D1-expression (p = 0.021) than squamous cell carcinomas. Ki67 showed an expression-spectrum from 15-95% but level of expression was not significantly associated to recurrence. Conclusion: Nuclear expression of cyclin D1 was found more often in adenocarcinomas in contrast to squamous cell carcinomas. Relapsing adenocarcinomas showed higher expression of cyclin D1. Neither the examination of cell cycle regulators nor ki67 can be transferred in a clinical setting yet. Further studies based on a greater number of relapsed tumours are needed.